Long-term results of postoperative radiochemotherapy with weekly cisplatin in head and neck cancer
VICTOR DUQUE-SANTANA,
Spain
PO-1096
Abstract
Long-term results of postoperative radiochemotherapy with weekly cisplatin in head and neck cancer
Authors: VICTOR DUQUE SANTANA1, Asunción Hervás Morón1, Jose Domínguez Rullán1, Carmen Vallejo Ocaña1, Margarita Martín Martín1, Mireia Valero Perena1, Rafael Moris Pablos2, David Sevillano Martinez3, Sonsoles Sancho García1
1Ramón y Cajal University Hospital, Radiation Oncology, Madrid, Spain; 2Ramón y Cajal University Hospital , Physics, Madrid, Spain; 3Ramón y Cajal University Hospital, Physics, Madrid, Spain
Show Affiliations
Hide Affiliations
Purpose or Objective
The purpose of this study is to analyze the results of over 16 years of experience with postoperative radiochemotherapy based on weekly Cisplatin 40mg/m2 in patients diagnosed with locally advanced head and neck cancer.
Material and Methods
Between March 2004 and April 2020, 133 consecutive patients diagnosed with resectable locally advanced head and neck cancer were treated in our department. All patients received adjuvant radiochemotherapy based on radiotherapy 66-70 Gy to areas with close surgical margin or extracapsular lymph node involvement and 50-54 Gy to the clinical target volume (CTV), concurrent with intravenous weekly cisplatin at 40mg/m2.
Results
The median age was 59 years (36-80), 106 patients were male (79.1%) and 27 were female (20.9%). The pathological stage were: 4 (3.0%) stage II, 13 (9.7%) stage III, 97 (72.9%) stage IVa and 19 (14.4%) stage IVb. Tumor sites: 46 (34.6%) larynx, 60 (45.1%) oral cavity, 20 (15.0%) oropharynx and 7 (5.3%) hypopharynx. 97 (72.9%) patients received at least 5 cycles of chemotherapy and 36 (27.1%) received less than 5 cycles of chemotherapy. 33 (24.8%) patients developed Grade III mucositis and 7 (5.3%) grade III neutropenia. After a median follow-up of 60 months (4-187), two and five-year overall survival (OS) were 76.9% and 59.5% respectively. Two and five-year cancer-specific survival were 82.6% and 70.3% respectively.
| PATIENTS CHARACTERISTICS (N=133) | |
Gender | | |
Male | 106 (79.1%) | |
Female | 27 (20.9%) | |
Age (years) | 59 (36-80), | |
|
Patological Stage AJCC | | |
II | 4 (3.1%) | |
III | 13 (9.7%) | |
IVA | 97 (72.9%) | |
IVB | 19 (14.3%%) | |
Tumor sites | | |
Larynx | 46 (34.6%) | |
Oral cavity | 60 (44.9%) | |
Oropharynx | 20 (14.9%) | |
Hypopharynx. | 7 (5.6%) | |
Chemotherapy | | |
≥ 5 cycles | 97 (72.9%) | |
<5 cycles | 36 (27.1%) | |
Grade III toxicity | | |
Mucositis | 33 (24.8%) | |
Neutropenia | 7 (5.26%) | |